Procter & Gamble Health Fair Value
Procter & Gamble Health (PGHL) average fair value is ₹2647.5 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹5503.5 (-51.89%), fair value range ₹308.82–₹5725.76. Read PGHL dividend history for the complete payout history and dividend yield track record.
Fair Value Analysis Export
PGHL Fair Value vs Current Price — Valuation Summary
PGHL average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Browse PGHL income statement for revenue, profit, balance sheet and cash flow data.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
PGHL Fair Value Analysis — Data Sources & Coverage
Procter & Gamble Health financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit PGHL screener.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
PGHL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Procter & Gamble Health P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.